



NATCO PHARMA LIMITED


Statement of consolidated Financial Results for the quarter and half year ended 30th September 2015

Rs.in lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS						
PARTICULARS	THREE MONTHS ENDED (UN-REVIEWED/UN-AUDITED)			YEAR-TO-DATE FIGURES FOR THE HALF YEAR ENDED ON (UN-REVIEWED/UN-AUDITED)		YEAR ENDED (AUDITED)
	30 September 2015	30 June 2015	30 September 2014	30 September 2015	30 September 2014	31 March 2015
01. Gross Sales/Income from Operations	23,730	22,745	21,532	46,475	41,341	80,306
Less: Excise Duty	812	531	267	1,343	633	1,295
Less: Sales Tax	641	645	359	1,286	772	1,591
Net Sales/Income from Operations	22,277	21,569	20,906	43,846	39,936	77,420
02. Other Operating Income	1,213	802	1,017	2,015	2,965	5,107
03. TOTAL INCOME FROM OPERATIONS	23,490	22,371	21,923	45,861	42,901	82,527
04. EXPENDITURE						
a) Cost of materials consumed	6,240	5,744	5,716	11,984	11,779	16,726
b) Purchases of stock-in-trade	2,315	2,388	-	4,703	-	8,428
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(1,819)	(1,148)	725	(2,967)	1,202	(917)
d) Employee benefits expense	4,304	4,026	3,368	8,330	6,525	13,692
e) Depreciation and amortization expense	1,268	1,264	1,115	2,532	2,228	4,726
f) Other Expenses	6,601	5,615	6,229	12,216	11,760	23,261
TOTAL EXPENSES	18,909	17,889	17,153	36,798	33,494	65,916
05. Profit/(Loss) from Operations before other income, finance costs and exceptional items	4,581	4,482	4,770	9,063	9,407	16,611
06. Other Income	207	183	319	390	437	1,491
07. Profit/(Loss) from ordinary activities before finance Cost and exceptional items	4,788	4,665	5,089	9,453	9,844	18,102
08. Finance costs	766	808	724	1,574	1,380	3,168
09. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items	4,022	3,857	4,365	7,879	8,464	14,934
10. Exceptional Item	-	-	-	-	-	1,513
11. Profit/(Loss) from ordinary activities before tax	4,022	3,857	4,365	7,879	8,464	13,421
12. Current Tax expense	1,018	1,017	1,241	2,035	2,119	3,512
13. Deferred Tax expense /(Reversal)	86	86	-	172	-	(3,117)
14. Net Profit/ (Loss) from ordinary activities after tax	2,918	2,754	3,124	5,672	6,345	13,026
15. Minority Interest	(39)	(69)	(113)	(108)	(238)	(435)
16. Net Profit/ (Loss) for the period	2,957	2,823	3,237	5,780	6,583	13,461
17. Paid-up Equity Share Capital(each share of Rs.10/-face value)	3,483	3,323	3,307	3,483	3,307	3,323
18. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	81,282
19. Earnings per share						
Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	8.84	8.50	9.79	17.34	19.91	40.64
	8.84	8.50	9.79	17.34	19.91	40.64
PART II : SELECT INFORMATION						
20. Public Share holding :						
a) Number of Shares	1,69,68,985	1,53,68,985	1,53,73,943	1,69,68,985	15373943	1,53,73,985
b) Percentage of Share holding	48.71	46.24	46.48	48.71	46.48	46.26
21. Promoters and Promoter Group Shareholding						
a) Pledged/Encumbered – No. of shares	-	-	-	-	0	-
b) Non-encumbered-No. of shares	1,78,65,864	1,78,65,864	1,76,99,131	1,78,65,864	1,76,99,131	1,78,60,864
Percentage (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	51.29	53.76	53.52	51.29	53.52	53.74

The above un-audited financial results were reviewed by the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Friday, the 13th November, 2015. There are no exceptional and extraordinary items to be reported for the period under review. The stand alone result are available on the company website www.natcopharma.co.in.

Dated at Hyderabad, this, the 13th day of November, 2015.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V. C. Nannapaneni
Chairman & Managing Director

Pending as on 01-07-2015	-
Received during the quarter	124
Resolved during the quarter	124
Pending as on 30-09-2015	-

Regd. Office: NATCO House, Road # 2, Banjara Hills, Hyderabad : 500 034



NATCO PHARMA LIMITED

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

Rs. In Lakhs

Particulars	As at 30-Sep-2015 (Un Reviewed)	As at 31-Mar-2015 (Audited)
Equity and Liabilities		
Shareholders' Funds		
a) Share Capital	3,483	3,323
b) Reserves and Surplus	1,20,348	81,282
Sub-total: Shareholders' funds	1,23,831	84,605
c) Minority Interest	498	503
Non-Current Liabilities		
a) Long term borrowings	359	9,702
b) Deferred tax liabilities (net)	1,361	1,189
c) Other long-term liabilities	77	83
d) Long term provisions	1,152	950
Sub-total: Non-current Liabilities	2,949	11,924
Current Liabilities		
a) Short term borrowings	10,884	16,854
b) Trade payables	17,025	12,530
c) Other current liabilities	9,125	11,856
d) Short-term provisions	116	133
Sub-total: Current Liabilities	37,150	41,373
TOTAL- EQUITY AND LIABILITIES	1,64,428	1,38,405
Assets		
Non-Current Assets		
a) Fixed Assets	-	
Tangible Assets	67,473	66,403
Intangible Assets	4,506	4,595
b) Capital Work-in-progress	15,963	12,896
c) Non- Current Investments	157	157
d) Long term loans and advances	7,222	5,703
e) Other non-current assets	998	354
Sub-total: Non-Current Assets	96,319	90,108
Current Assets		
a) Current Investments	2,012	12
b) Inventories	27,423	22,000
c) Trade receivables	20,340	19,243
d) Cash and Cash Equivalents	7,654	1,336
e) Short term loans and advances	10,153	5,515
f) Other Current Assets	527	191
Sub-total: Current Assets	68,109	48,297
TOTAL- ASSETS	1,64,428	1,38,405